EFFICACY OUTCOMES OF PLACEBO MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RESPONDED TO PLACEBO INDUCTION THERAPY: RESULTS FROM THE PHASE 3 COMMAND STUDY

被引：0
|
作者：
Atreya, Raja
Ferrante, Marc
Afzali, Anita
Bamias, Giorgos
Long, Millie D.
Neimark, Ezequiel
Levine, Phillip
Cheng, Ling
Kalabic, Jasmina
Hecht, Patrick
Vladea, Ramona C.
Schreiber, Stefan
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1792
引用
收藏
页码：S815 / S816
页数：2
相关论文
共 50 条
  • [21] One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
    Sandborn, W. J.
    Colombel, J. -F.
    D'Haens, G.
    Van Assche, G.
    Wolf, D.
    Kron, M.
    Lazar, A.
    Robinson, A. M.
    Yang, M.
    Chao, J. D.
    Thakkar, R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) : 204 - 213
  • [22] Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Ilo, Dapo
    Klaff, Justin
    Levy, Gweneth
    Yao, Xuan
    Chen, Su
    Gonzalez, Yuri Sanchez
    Hebuterne, Xavier
    Lindsay, James
    Higgins, Peter D. R.
    Cao, Qian
    Nakase, Hiroshi
    Colombel, Jean-Frederic
    Loftus, Edward V., Jr.
    Panaccione, Remo
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 976 - 989
  • [23] Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension study
    Atreya, R.
    Louis, E.
    Loftus Jr., E., V
    Rubin, D. T.
    Dubinsky, M.
    Hisamatsu, T.
    Kalabic, J.
    Mendez, P.
    Chen, S.
    Shah, S.
    Morisset, P.
    Duan, W. R.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i104 - i106
  • [24] EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
    Feagan, Brian G.
    Loftus, Edward V.
    Danese, Silvio
    Vermeire, Severine
    Sandborn, William J.
    Ritter, Timothy E.
    Mehta, Rajiv
    Seidler, Ursula
    Seibold, Frank
    Beales, Ian
    Kim, Hyo Jong
    McNally, John
    Yun, Chohee
    Zhao, Sally
    Liu, Xiaopeng
    Tasset, Chantal T.
    Besuyen, Robin
    Watanabe, Mamoru
    Schreiber, Stefan
    Rogler, Gerhard
    Hibi, Toshifumi
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2021, 160 (06) : S125 - S125
  • [25] The Efficacy of Induction Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Allegretti, Jessica R.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Shipitofsky, Nicole
    Miao, Ye
    Zhang, Hongyan
    Bortlik, Martin
    Hlavaty, Tibor
    Fujii, Toshimitsu
    Feagan, Brian G.
    Sands, Bruce E.
    Dignass, Axel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S806 - S807
  • [26] Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi S.
    Huang, Kuan-Hsiang Gary
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    QUASAR Study Grp
    LANCET, 2025, 405 (10472): : 33 - 49
  • [27] Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study
    Sridhar, S.
    Hart, A.
    Venkat, S.
    Huang, K. H. G.
    Yarandi, S.
    Germinaro, M.
    Vetter, M.
    Rubin, D. T.
    Dignass, A.
    Cua, D.
    Freeman, T.
    Waterworth, D.
    Mcrae, B.
    Verstockt, B.
    Branigan, P.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i422 - i422
  • [28] A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-Maintenance
    Sandborn, William
    Feagan, Brian
    Marano, Colleen
    Strauss, Richard
    Johanns, Jewel
    Zhang, Hongyan
    Guzzo, Cynthia
    Colombel, Jean-Frederic
    Reinisch, Walter
    Gibson, Peter
    Collins, Judy
    Jarnerot, Gunnar
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S673 - S674
  • [29] Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
    Rubin, David T.
    Dotan, Iris
    DuVall, Aaron
    Bouhnik, Yoram
    Radford-Smith, Graham
    Higgins, Peter D. R.
    Mishkin, Daniel S.
    Arrisi, Pablo
    Scalori, Astrid
    Oh, Young S.
    Tole, Swati
    Chai, Akiko
    Chamberlain-James, Kirsten
    Lacey, Stuart
    McBride, Jacqueline
    Panes, Julian
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 17 - 27
  • [30] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
    Sandborn, W. J.
    Ferrante, M.
    Bhandari, B. R.
    Berliba, E.
    Hibi, T.
    D'Haens, G. Geert R.
    Tuttle, J.
    Krueger, K.
    Friedrich, S.
    Durante, M.
    Arora, V.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
12345